-
Research and Reports in Urology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Pazopanib and anti-VEGF therapy
Review
(2540) Views (1030) Full article downloads
Author: Harry A Drabkin
Published Date March 2010
Volume 2010:2 Pages 35 - 40
DOI: http://dx.doi.org/10.2147/RRU.S5896
Harry A Drabkin
Medical University of South Carolina and Hollings Cancer Center, Charleston, SC, USA
Abstract: Pazopanib (VotrientTM, GlaxoSmithKline), a multi-kinase inhibitor with activity against VEGFR and other receptors, was recently approved by the FDA for the treatment of advanced renal cell carcinoma (RCC). Here, we review the history of its development, together with an overview of VEGF and its receptors and co-receptors. Results from selected clinical trial data in RCC and other malignant diseases are presented. Based on available evidence, pazopanib is an effective VEGFR inhibitor with demonstrable clinical activity in metastatic RCC and promising activity in other diseases. Like most kinase inhibitors, its activity is not restricted to VEGF receptors, which is reflected in its side-effect profile.
Keywords: pazopanib, VEGFR, renal cell carcinoma
- Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
- Distal femoral opening-wedge osteotomy for lateral compartment osteoarthritis of the knee
- Gamma knife radiosurgery for uveal melanoma ineligible for brachytherapy by the Collaborative Ocular Melanoma Study criteria
- Ipsilateral pedicle screw placement with contralateral percutaneous facet screws: Early results with an alternative in lumbar arthrodesis
- Successful conservative treatment of chylous ascites as rare intermediate complication after resection of an aboral esophageal carcinoma
